BRIGHT MINDS BIOSCIENCES INC.
About BRIGHT MINDS BIOSCIENCES INC.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $677.0M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $677.0M
- Shares outstanding
- 11.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 8, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BRIGHT MINDS BIOSCIENCES INC..
Write a review
News about BRIGHT MINDS BIOSCIENCES INC.
News & sentiment via Polygon.io
